

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

1. (Currently Amended) A method for inhibiting endothelial cell adhesion, endothelial cell migration and/or angiogenesis, comprising administering to a subject in need thereof an effective amount of:

(a) an isolated peptide consisting of at least 18 amino acids, comprising tyrosine-histidine (Y-H) or asparagine-histidine (N-H), and at least three hydrophobic amino acids with bulky side chains; or

(b) a mutant or derivative of the peptide (a), in which the tyrosine-histidine (Y-H) or asparagine-histidine (N-H) in the peptide (a) was substituted with amino acids selected from the group consisting of serine-histidine (S-H), histidine-histidine (H-H), phenylalanine-histidine (F-H), threonine-histidine (T-H), tyrosine-asparagine (Y-N) and alanine-alanine (A-A);

comprising an amino acid sequence represented by (I, D, E or K)-(E, A or Q)-L-(L, R or A)-(N, D or S)-(A, L, K or I)-(L or Y)-(R, N, L or K)-(Y or N)-H-(M, I or G)-(V, L, Q or G)-(G, K, T or D)-(R, S, L or E)-(R, A, E or I)-(V, M, T or L)-(L, C or V)-(T, A, G or S).

2-3. (Canceled).

4. (Currently Amended). The method of Claim 1 ~~3~~, wherein the peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 23 to SEQ ID NO: 26.

5. (Original) The method of Claim 1, wherein the peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 17 to SEQ ID NO: 22.

6. (Original) The method of Claim 5, wherein the peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 11 to SEQ ID NO: 16.

7. (Currently Amended) A method for the treatment ~~or prevention~~ of angiogenesis-related diseases, comprising administering to a subject in need thereof an effective amount of:

~~(a) an isolated peptide consisting of at least 18 amino acids, comprising tyrosine-histidine (Y-H) or asparagine-histidine (N-H), and at least three hydrophobic amino acids with bulky side chains; or~~

~~(b) a mutant or derivative of the peptide (a), in which the tyrosine-histidine (Y-H) or asparagine-histidine (N-H) in the peptide (a) was substituted with amino acids selected from the group consisting of serine-histidine (S-H), histidine-histidine (H-H), phenylalanine-histidine (F-H), threonine-histidine (T-H), tyrosine-asparagine (Y-N) and alanine-alanine (A-A);~~

comprising an amino acid sequence represented by (I, D, E or K)-(E, A or Q)-L-(L, R or A)-(N, D or S)-(A, L, K or I)-(L or Y)-(R, N, L or K)-(Y or N)-H-(M, I or G)-(V, L, Q or G)-(G, K, T or D)-(R, S, L or E)-(R, A, E or I)-(V, M, T or L)-(L, C or V)-(T, A, G or S).

8. (Original) The method of Claim 7, the angiogenesis-related diseases are selected from the group consisting of cancer, vascular malformation, arteriosclerosis, vascular adhesions, edematous sclerosis, corneal graft neovascularization, neovascular glaucoma, diabetic retinopathy, pterygium, retinal degeneration, retrolental fibroplasia, granular conjunctivitis, rheumatoid arthritis, systemic Lupus erythematosus, thyroiditis, psoriasis, capillarectasia, pyogenic granuloma, seborrheic dermatitis and acne.

9-12. (Canceled).